How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

26 results for

Emergency Pediatric Dosing 10-11 kilogram

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. Emergency Pediatric Dosing 10-11 kilogram

Emergency Pediatric Dosing 10-11 kilogram Emergency Pediatric Dosing 10-11 kilogram Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 (...) Emergency Pediatric Dosing 10-11 kilogram Emergency Pediatric Dosing 10-11 kilogram Aka: Emergency Pediatric Dosing 10-11 kilogram , Broselow Purple II. Criteria: Body habitus Age: 11-18 months Length: 74 to 84.5 cm Weight: 10-11 kg (mean 10.5 kg) III. Findings: Vital Signs (normal) : 110-170/minute : 20-30/minute Systolic : 70-110 mmHg IV. Medications: Rapid Sequence Intubation (RSI) and intubation and ventilation Induction (Sedation) 3.2 mg 20 mg 32 mg Paralytic 20 mg 10 mg 1 mg Sedation Maintenance

2018 FP Notebook

2. Emergency Pediatric Dosing 10-11 kilogram

Emergency Pediatric Dosing 10-11 kilogram Emergency Pediatric Dosing 10-11 kilogram Toggle navigation Brain Head & Neck Chest Endocrine Abdomen Musculoskeletal Skin Infectious Disease Hematology & Oncology Cohorts Diagnostics Emergency Findings Procedures Prevention & Management Pharmacy Resuscitation Trauma Emergency Procedures Ultrasound Cardiovascular Emergencies Lung Emergencies Infectious Disease Pediatrics Neurologic Emergencies Skin Exposure Miscellaneous Abuse Cancer Administration 4 (...) Emergency Pediatric Dosing 10-11 kilogram Emergency Pediatric Dosing 10-11 kilogram Aka: Emergency Pediatric Dosing 10-11 kilogram , Broselow Purple II. Criteria: Body habitus Age: 11-18 months Length: 74 to 84.5 cm Weight: 10-11 kg (mean 10.5 kg) III. Findings: Vital Signs (normal) : 110-170/minute : 20-30/minute Systolic : 70-110 mmHg IV. Medications: Rapid Sequence Intubation (RSI) and intubation and ventilation Induction (Sedation) 3.2 mg 20 mg 32 mg Paralytic 20 mg 10 mg 1 mg Sedation Maintenance

2015 FP Notebook

3. Single-Dose Phase 1 Study of TAK-792

-2 [ Time Frame: Day -1: pre-dose and Day 1 (2.5 hours post dose) ] Cmax: Maximum Observed Plasma Concentration for Total BCAA Parameter in Cohorts 4a-2, 4b-2, 5a-2 and 5b-2 [ Time Frame: Day -1: pre-dose and Day 1 at multiple time points (0.5, 1, 1.5, 2, 2.5, 4, 5, 6, 10, 11, 12, 24 hours; up to 24 hours) post-dose ] Tmax: Time to Reach the Cmax for Total BCAA Parameter in Cohorts 4a-2, 4b-2, 5a-2 and 5b-2 [ Time Frame: Day -1: pre-dose and Day 1 at multiple time points (0.5, 1, 1.5, 2, 2.5, 4 (...) , 5, 6, 10, 11, 12, 24 hours; up to 24 hours) post-dose ] Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Layout table for eligibility information Ages Eligible for Study

2015 Clinical Trials

4. The economic evaluation of early intervention with Anti-Tumor Necrosis Factor-alpha treatments in pediatric Crohn's disease

The economic evaluation of early intervention with Anti-Tumor Necrosis Factor-alpha treatments in pediatric Crohn's disease The Hospital for Sick Children Technology Assessment at SickKids (TASK) FULL REPORT THE ECONOMIC EVALUATION OF EARLY INTERVENTION WITH ANTI-TUMOR NECROSIS FACTOR-a TREATMENTS IN PEDIATRIC CROHN’S DISEASE Authors: Naazish S. Bashir, MSc, MBA, PhD Research Fellow, Child Health Evaluative Sciences, The Hospital for Sick Children, Toronto, Canada Thomas D. Walters, MD, MSc (...) -a treatment following immunomodulator treatment has not been completed in newly diagnosed children with CD. However an RCT using infliximab as first-line (top-down) therapy in naïve pediatric CD patients has been started (Cozijnsen, van Pieterson, Samsom, Escher, & de Ridder, 2016). A recent RCT in adult CD patients examining the early intervention with three induction doses of anti-TNF-a followed by thiopurine monotherapy (“top-down” approach) showed a greater proportion of patients (60.0%) in remission

2019 SickKids Reports

5. First- and Second-Generation Antipsychotics in Children and Young Adults: Systematic Review Update

in raw measure of kilograms (kg) and kg·m -2 , which led to higher values used for between-group differences in weight and BMI: mean weight change for lurasidone (doses pooled) versus placebo was 0.45 kg not 2.67 kg, and mean change in BMI was 0.15 kg·m -2 rather than 2.92 kg·m -2 . We updated the following analyses for Key Question 2 about the effect of olanzapine compared with lurasidone on weight gain and BMI: network meta-analysis for body composition outcomes across all conditions; analysis (...) , Feinstein Institute for Medical Research Glen Oaks, NY Jana Davidson, M.D., FRCPC Psychiatrist-in-Chief, B.C. Children’s Hospital, PHSA Clinical Professor, Psychiatry Head, Division of Child & Adolescent Psychiatry at University of British Columbia Vancouver, BC, Canada Gregory Gale, M.D. Medical Director, Behavioral Health LifeSynch-HUMANA Irving, TX Michael Naylor, M.D. Director, Behavioral Health and Welfare Program Director, Comprehensive Assessment and Response Training System vi Director, Clinical

2017 Effective Health Care Program (AHRQ)

6. Management of Suspected Opioid Overdose with Naloxone by Emergency Medical Services Personnel

With Naloxone by Emergency Medical Services Personnel Structured Abstract Objectives. To compare different routes, doses, and dosing strategies of naloxone administration for suspected opioid overdose by emergency medical services (EMS) personnel in field settings, and to compare effects of transport to a health care facility versus nontransport following successful reversal of opioid overdose with naloxone. Methods. Four databases were searched through September 2017. Additional studies were identified (...) framework * Patients with confirmed or suspected opioid overdose who exhibit altered mental status, miosis, or respiratory distress and who are treated in the out-of-hospital setting by emergency medical services personnel †Administration of naloxone hydrochloride via the nasal, intravenous, intramuscular, or subcutaneous injection (including the naloxone auto-injector) ‡ Key Question 1 addresses comparisons involving route of administration and dose; Key Question 2 addresses comparisons involving dose

2017 Effective Health Care Program (AHRQ)

7. Antibody-Mediated Rejection in Cardiac Transplantation: Emerging Knowledge in Diagnosis and Management Full Text available with Trip Pro

predictive of CAV (indirectly, AMR correlates with DSA, DSA correlates with CAV) 35 2010 Nath Histopathology and immunopathology 65 … 15% of patients AMR/CAV AMR predictive of CAV (indirectly, AMR correlates with anti-MICA, anti-MICA correlates with CAV) Immunopathology was conducted only on cases with suspicious histopathology or on clinical request. The following sets in parentheses represent multiple manuscripts from the same institutional transplantation program: (1, 2, 5, 18, 22); (10, 11, 24, 29 (...) Antibody-Mediated Rejection in Cardiac Transplantation: Emerging Knowledge in Diagnosis and Management Antibody-Mediated Rejection in Cardiac Transplantation: Emerging Knowledge in Diagnosis and Management | Circulation Search Hello Guest! Login to your account Email Password Keep me logged in Search March 2019 March 2019 March 2019 March 2019 March 2019 February 2019 February 2019 February 2019 February 2019 January 2019 January 2019 January 2019 January 2019 January 2019 This site uses

2015 American Heart Association

8. Programmatic management of latent tuberculosis infection in the European Union

-resistant TB) • Risk of progression to active TB over time in infected persons, with or without LTBI treatment • Cost of LTBI in the EU/EEA • Identification of the most reliable tests for diagnosis of LTBI with the highest yield in different epidemiological settings (e.g. high and low TB burden) and populations (e.g. immunocompromised patients, children, migrants and close contacts of TB patients) • The effect of tests being free of charge • Assessment of strategies for improved screening and case

2019 European Centre for Disease Prevention and Control - Public Health Guidance

9. Crizanlizumab, Voxelotor, and L-Glutamine for Sickle Cell Disease: Effectiveness and Value

, voxelotor, and L-glutamine for which she is the Site Principal Investigator. Keith Quirolo, MD Former Director of Pediatric Sickle Cell Program Former Clinical Director of Apheresis Program UCSF Benioff Children's Hospital Oakland No relevant conflicts of interest to disclose, defined as more than $10,000 in health care company stock or more than $5,000 in honoraria or consultancies during the previous year from health care manufacturers or insurers. Ahmar Zaidi, MD Comprehensive Sickle Cell Program (...) Assistant Professor of Pediatrics Wayne State University School of Medicine, Central Michigan University School of Medicine Children's Hospital of Michigan Dr. Zaidi reports grants and personal fees from Emmaus Life Sciences, grants, personal fees and speaker bureau affiliation from Global Blood Therapeutics, and personal fees from Novartis. ©Institute for Clinical and Economic Review, 2020 Page 5 Evidence Report - Crizanlizumab, Voxelotor, and L-Glutamine for SCD Return to Table of Contents Table

2020 California Technology Assessment Forum

10. Risk factors for breast cancer: A review of the evidence 2018

if they presented further information about a specific epidemiological element, such as different sub– exposures or a dose–response analysis. If there was significant overlap in included studies, then these additional meta–analyses were excluded. Overlap in studies contained within the various meta–analyses was not systematically explored for all factors. 2.4 Data extraction and synthesis After the search and study selection process, applicable full–text papers were retrieved for data extraction and analysis

2018 Cancer Australia

11. Guselkumab (Tremfya) - Psoriasis

around 60 years, after which the incidence is lower 5 . Approximately 90% of those affected with psoriasis have plaque psoriasis 7,8,6 , with 20% having moderate to severe plaque psoriasis with a body surface area (BSA) involvement of >5% 9 . 2.1.3. Aetiology and pathogenesis The pathogenesis of psoriasis involves environmental factors and immune dysregulation in genetically- predisposed individuals 10, 11 . Substantial evidence indicates that IL-23 plays an important role in innate and adaptive (...) -clinical aspects 31 2.3.7. Conclusion on the non-clinical aspects 33 2.4. Clinical aspects 34 2.4.1. Introduction 34 2.4.2. Pharmacokinetics 35 2.4.3. Pharmacodynamics 40 2.4.4. Discussion on clinical pharmacology 45 2.4.5. Conclusions on clinical pharmacology 47 2.5. Clinical efficacy 47 2.5.1. Dose response studies 47 2.5.2. Main studies 50 Study CNTO1959PSO3003 (NAVIGATE) 53 Study CNTO1959PSO3003 (NAVIGATE) 57 Study CNTO1959PSO3003 (NAVIGATE) 58 2.5.3. Discussion on clinical efficacy 104 2.5.4

2017 European Medicines Agency - EPARs

12. Psychological and Pharmacological Treatments for Adults With Posttraumatic Stress Disorder: A Systematic Review Update

= 0.3233 G2 vs. G3, p = 0.5396 NR F-218 Author Year Intervention Groups Subgroup Analyzed Comorbid Condition QOL Disability/Function al Impairment Return to Work/Duty Resick et al., 2002 3 Resick et al., 2003 125 Resick et al., 2012 126 G1: CBT, CPT G2: CBT, exposure- based therapy (PE) G3: WL Exposure to Child Trauma BDI Mean (SD) No Childhood Sexual Abuse Pre-tx: 22.4 (9.5) Post-tx: 10.0 (8.3) 9 mth FU: 10.9 (9.1) Childhood Sexual Abuse Pre-tx: 24.9 (9.1) Post-tx: 11.4 (10.4) 9 mth FU: 12.9 (12.7 (...) , -1.52 to -0.65) Moderate Cognitive therapy PTSD symptoms a 4 (283) 5, 7-9 Reduced PTSD symptoms SMD of individual studies range from -2.0 to -0.3 Moderate Loss of PTSD diagnosis 4 (283) 5, 7-9 Greater loss of PTSD diagnosis RD 0.55 (95% CI, 0.28 to 0.82) Moderate Depression symptoms b 4 (283) 5, 7-9 Reduced depression symptoms Between-group mean differences of individual trials ranged from -11.1 to - 8.3 Moderate Cognitive behavioral therapy-exposure PTSD symptoms a 13 (885) 3, 10-21 8 (689) 3, 10

2018 Effective Health Care Program (AHRQ)

13. Heart Disease and Stroke Statistics 2017 Update: A Report From the American Heart Association Full Text available with Trip Pro

Cardiac Arrest (Chapter 18) • In the 2015 CARES (Cardiac Arrest Registry to Enhance Survival) National Survival Report for emergency medical services–treated nontrau- matic cardiac arrest, the survival rate to hospital discharge was 10.6% for adults >18 years old, 23.5% for children 13 to 18 years old, 16.6% for children >1 to 12 years old, and 6.2% for children 0. • Coronary artery calcium scores >400 versus 0 are associated with an increased risk for can- cer, chronic kidney disease, pneumonia (...) Sandeep R. Das University of Texas Southwestern Medical Center None None None None None None None Rajat Deo University of Pennsylvania NIH† None None None None Boehringer Ingelheim*; Janssen Pharmaceuticals* None Sarah D. de Ferranti Children's Hospital Boston Pediatric Heart Network, NHLBI (coPI on upcoming pediatric prevention trial)* None None None None None None James Floyd University of Washington None None None None None None None Myriam Fornage University of Texas Health Science Center

2017 American Heart Association

14. Wakix - pitolisant. Narcolepsy

European Medicines Agency ESS Epworth Sleepiness Scale ESSB ESS Baseline value ESSF ESS Final value EU European Union FDA US Food and Drug Administration FUA Follow-up advice GCP Good Clinical Practice ITT Intention to Treat (population) kg Kilogram LOCF Last Observation Carried Forward mg Milligram Ml Millilitre MSLT Multiple Sleep Latency Test MWT Maintenance of Wakefulness Test ng Nanogram OR Odds Ratio PD Pharmacodynamics PDCO Paediatric Committee (European Medicines Agency) PIP Paediatric (...) on clinical pharmacology 38 2.4.5. Conclusions on clinical pharmacology 40 2.5. Clinical efficacy 40 2.5.1. Dose response studies 41 2.5.2. Main studies 43 2.5.3. Discussion on clinical efficacy 65 2.5.4. Conclusions on the clinical efficacy 67 2.6. Clinical safety 67 2.6.1. Discussion on clinical safety 77 2.6.2. Conclusions on the clinical safety 82 2.7. Risk Management Plan 82 2.8. Pharmacovigilance 95 2.9. Product information 95 2.9.1. User consultation 95 2.9.2. Labelling exemptions 95 2.9.3

2016 European Medicines Agency - EPARs

15. Darzalex (daratumumab) - multiple myeloma

aspects 28 2.4.1. Introduction 28 2.4.2. Pharmacokinetics 29 2.4.3. Pharmacodynamics 34 2.4.4. Discussion on clinical pharmacology 39 2.4.5. Conclusions on clinical pharmacology 41 2.5. Clinical efficacy 42 2.5.1. Dose response studies 42 2.5.2. Main studies 44 2.5.3. Discussion on clinical efficacy 86 2.5.4. Conclusions on the clinical efficacy 88 2.6. Clinical safety 88 2.6.1. Discussion on clinical safety 104 2.6.2. Conclusions on the clinical safety 107 2.7. Risk Management Plan 108 2.8 (...) Committee IRR infusion related reaction IV intravenous Assessment report EMA/278085/2016 Page 5/119 kg kilogram LC light chain LEN lenalidomide LLOQ Lower Limit of Quantification LMW Low molecular weight mAb monoclonal antibody mg milligram min minute mL milliliter MM Multiple myeloma MR minimal response MS Mass spectrometry MVM minute virus of mice MRPP Maximal reduction in paraprotein NE not evaluable NGD nicotinamide guanine dinucleotide NK natural killer NR Not reported ORR overall response rate OS

2016 European Medicines Agency - EPARs

16. Akynzeo (netupitant / palonosetron)

at steady state Open-label 1 way Healthy subjects 8M, 8F Netupitant 450 mg on Day 8 NETU-10-08 PK interaction between Netupitant/Palonosetron and Ethinylestradiol / Levonorgestrel Randomised, open-label, 2-way crossover Healthy subjects 24F Single dose, Netupitant/Palonosetron FDC 300/0.5 mg NETU-10-11 PK interaction between Netupitant/Palonosetron with Ketoconazole and Rifampicine Randomised, open-label, 2-group, 2-way crossover Healthy subjects Ketoconazole: 11M, 6F Rifampicine: 10M, 8F Single dose (...) -period crossover Healthy subjects 9M, 9F Single dose PO, Netupitant 450 mg, Palonosetron 0.75 mg NETU-07-01 PK interaction between Netupitant and Digoxine at steady state Open-label 1 way Healthy subjects 8M, 8F Netupitant 450 mg on Day 8 NETU-10-08 PK interaction between Netupitant/Palonosetron and Ethinylestradiol / Levonorgestrel Randomised, open-label, 2-way crossover Healthy subjects 24F Single dose, Netupitant/Palonosetron FDC 300/0.5 mg NETU-10-11 PK interaction between Netupitant/Palonosetron

2015 European Medicines Agency - EPARs

17. Developing evidence informed, employer-led workplace health

by continuous improvement policies, intervention duration/dose and employee engagement. However, these characteristics were not mentioned in any views studies or policy documents as being important to workplace health intervention success. The importance of the intervention implementer’s approach and the use of Internet technologies were discussed in views studies; however, these have yet to be evaluated in systematic reviews or integrated into policy documents. These comparisons of characteristics across (...) via booklets and/or diaries was seen as a successful tool for engaging employees. • Appropriate use of external versus peer providers: although peer providers were not discouraged, due to proximity in the working environment, participants would be less likely to seek their support, suggesting that employers may want to consider peers from external sources. Intervention duration/dose Three reviews provided insight into the role of intervention duration or dose on the potential success of workplace

2016 EPPI Centre

18. Assessing Fitness to Drive

the ambit of ordinary road laws. Drivers who are given special exemptions from these laws, such as emergency service vehicle drivers, should have a risk assessment and an appropriate level of medical standard applied by the employer. At a minimum, they should be assessed to the commercial vehicle standard. 1.3.2 Short-term fitness to drive This publication does not attempt to address the full range of health conditions that might impact on a person‘s fitness to drive in the short term. Some guidance (...) such as checking loads, conversing with passengers and undertaking emergency procedures) without first undertaking a task risk assessment that identifies the range of other requirements for a particular job. 1.4 Content This publication is presented in three parts. Part A comprises general information including: • the principles of assessing fitness to drive • specific considerations including - the assessment of people with multiple medical conditions or age-related change - the management of temporary

2016 Cardiac Society of Australia and New Zealand

19. Remsima - infliximab

/589317/2013 Page 3/105 Paediatric ulcerative colitis Remsima is indicated for treatment of severely active ulcerative colitis, in children and adolescents aged 6 to 17 years, who have had an inadequate response to conventional therapy including corticosteroids and 6-MP or AZA, or who are intolerant to or have medical contraindications for such therapies. Ankylosing spondylitis Remsima is indicated for treatment of severe, active ankylosing spondylitis, in adult patients who have responded (...) the authorisation of Remsima as a biosimilar medicinal product containing infliximab. This is the first time that such recommendation is given in the European Union for a biosimilar monoclonal antibody. The therapeutic indications as well as the dosing regimen are the same as those of Remicade; the pharmaceutical form (powder for concentrate for solution for infusion) and strength (100 mg infliximab per vial) are also the same. In order to support this authorisation, the results of an extensive comparability

2013 European Medicines Agency - EPARs

20. Inflectra - infliximab

for such therapies. Paediatric ulcerative colitis Inflectra is indicated for treatment of severely active ulcerative colitis, in children and adolescents aged 6 to 17 years, who have had an inadequate response to conventional therapy including corticosteroids and 6-MP or AZA, or who are intolerant to or have medical contraindications for such therapies. Ankylosing spondylitis Inflectra is indicated for treatment of severe, active ankylosing spondylitis, in adult patients who have responded inadequately (...) (CHMP) recommended the authorisation of Inflectra as a biosimilar medicinal product containing infliximab. This is the first time that such recommendation is given in the European Union for a biosimilar monoclonal antibody. The therapeutic indications as well as the dosing regimen are the same as those of Remicade; the pharmaceutical form (powder for concentrate for solution for infusion) and strength (100 mg infliximab per vial) are also the same. In order to support this authorisation, the results

2013 European Medicines Agency - EPARs

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>